{
    "eid": "2-s2.0-85142627329",
    "title": "Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma",
    "cover-date": "2022-11-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Catalysis",
            "@code": "1503",
            "@abbrev": "CENG"
        },
        {
            "@_fa": "true",
            "$": "Molecular Biology",
            "@code": "1312",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Spectroscopy",
            "@code": "1607",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Computer Science Applications",
            "@code": "1706",
            "@abbrev": "COMP"
        },
        {
            "@_fa": "true",
            "$": "Physical and Theoretical Chemistry",
            "@code": "1606",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Organic Chemistry",
            "@code": "1605",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Inorganic Chemistry",
            "@code": "1604",
            "@abbrev": "CHEM"
        }
    ],
    "keywords": [
        "Bax",
        "Bcl-2 family proteins",
        "Bcl-xL",
        "bortezomib resistance",
        "mantle cell lymphoma",
        "O-GlcNAcylation"
    ],
    "authors": [
        "Sudjit Luanpitpong",
        "Montira Janan",
        "Juthamas Yosudjai",
        "Jirarat Poohadsuan",
        "Pithi Chanvorachote",
        "Surapol Issaragrisil"
    ],
    "citedby-count": 0,
    "ref-count": 52,
    "ref-list": [
        "Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management",
        "2016 US lymphoid malignancy statistics by World Health Organization subtypes",
        "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management",
        "Bortezomib for the treatment of mantle cell lymphoma",
        "Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study",
        "Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre Phase 2 clinical trial",
        "Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era",
        "Mantle cell lymphoma in relapse: The role of emerging new drugs",
        "Multidrug resistance in cancer: Role of ATP-dependent transporters",
        "Cytochrome P450 enzymes: Novel options for cancer therapeutics",
        "Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks",
        "Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation",
        "Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance",
        "Deciphering the elevated lipid via CD36 in mantle cell lymphoma with bortezomib resistance using synchrotron-based Fourier transform infrared spectroscopy of single cells",
        "Cell cycle-mediated drug resistance: An emerging concept in cancer therapy",
        "B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma",
        "STK38 is a critical upstream regulator of MYC\u2019s oncogenic activity in human B-cell lymphoma",
        "Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinasein mantle cell lymphoma",
        "Discovery of Hippo in MCL",
        "Targeting Wnt pathway in mantle cell lymphoma-initiating cells",
        "DAVID: Database for annotation, visualization, and integrated discovery",
        "Interleukin-27 induces interferon-inducible genes: Analysis of gene expression profiles using Affymetrix microarray and DAVID",
        "Mechanisms of action of Bcl-2 family proteins",
        "BCL-2 family proteins: Changing partners in the dance towards death",
        "Bax, Bak and beyond\u2013mitochondrial performance in apoptosis",
        "Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer",
        "Regulation of pro-apoptotic BH3-only proteins and its contribution to cancer progression and chemoresistance",
        "Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis",
        "A little sugar goes a long way: The cell biology of O-GlcNAc",
        "O-GlcNAcylation and metabolic reprogramming in cancer",
        "Inhibition of O-GlcNAcase sensitizes apoptosis and reverses bortezomib resistance in mantle cell lymphoma through modification of truncated Bid",
        "Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma",
        "Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma",
        "Nitric oxide and aggressive behavior of lung cancer cells",
        "Multifunctional role of Bcl-2 in malignant transformation and tumorigenesis of Cr(VI)-transformed lung cells",
        "The BCL-2 protein family, BH3-mimetics and cancer therapy",
        "Bcl-2 antiapoptotic family proteins and chemoresistance in cancer",
        "Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance",
        "Tipping the balance: Toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma",
        "BCL2-family dysregulation in B-cell malignancies: From gene expression regulation to a targeted therapy biomarker",
        "Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas",
        "Roles and regulation of BCL-xL in hematological malignancies",
        "The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression",
        "Expression of bcl-xL can confer a multidrug resistance phenotype",
        "Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL",
        "Direct activation of Bax protein for cancer therapy",
        "Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma",
        "Balancing cell life and death: Bax, apoptosis, and breast cancer",
        "Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma",
        "BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis",
        "Mito-priming as a method to engineer Bcl-2 addiction",
        "Lentivirus-delivered stable gene silencing by RNAi in primary cells"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "105816640",
            "affilname": "Wattanosoth Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/105816640",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Siriraj Foundation for Stem Cell Research",
        "Mahidol University",
        "National Research Council of Thailand"
    ]
}